Updated risk factors should be used to predict development of diabetes.

[1]  M. Laakso,et al.  Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort , 2015, Diabetologia.

[2]  G. Can,et al.  Low "quotient" Lp(a) concentration mediates autoimmune activation and independently predicts cardiometabolic risk. , 2014, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[3]  Shah Ebrahim,et al.  Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalink , 2014, BMC Cardiovascular Disorders.

[4]  R. Califf,et al.  A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk. , 2013, The American journal of cardiology.

[5]  S. de Servi,et al.  Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. , 2013, The American journal of cardiology.

[6]  K. Bennett,et al.  Statins and risk of treated incident diabetes in a primary care population. , 2013, British journal of clinical pharmacology.

[7]  N. Wareham,et al.  Change in HbA1c over 3 years does not improve the prediction of cardiovascular disease over and above HbA1c measured at a single time point , 2013, Diabetologia.

[8]  V. Basevi.  Standards of Medical Care in Diabetes—2013 , 2012, Diabetes Care.

[9]  Jason C. Fish,et al.  Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[10]  J. Manson,et al.  Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. , 2012, Archives of internal medicine.

[11]  P. Toth.  Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis , 2012 .

[12]  Paul Welsh,et al.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.

[13]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[14]  B. J. Gersh.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2011 .

[15]  P. Ridker,et al.  Lipoprotein(a) and risk of type 2 diabetes. , 2010, Clinical chemistry.

[16]  M. Laakso,et al.  Effect of nateglinide on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.

[17]  M. Laakso,et al.  Effect of valsartan on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.

[18]  Yasuo Ohashi,et al.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[19]  N. Cook,et al.  Reclassification Calculations for Persons With Incomplete Follow-up , 2010 .

[20]  C. D. A. Stehouwer,et al.  The Evaluation of Screening and Early Detection Strategies for Type 2 Diabetes and Impaired Glucose Tolerance (DETECT-2) update of the Finnish diabetes risk score for prediction of incident type 2 diabetes , 2010, Diabetologia.

[21]  Aziz Sheikh,et al.  Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore , 2009, BMJ : British Medical Journal.

[22]  F. Hu,et al.  A prediction model for type 2 diabetes risk among Chinese people , 2009, Diabetologia.

[23]  R. D'Agostino,et al.  Genotype score in addition to common risk factors for prediction of type 2 diabetes. , 2008, The New England journal of medicine.

[24]  R. Califf,et al.  Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. , 2008, American heart journal.

[25]  Heejung Bang,et al.  Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. , 2005, Diabetes care.

[26]  Jaakko Tuomilehto,et al.  The diabetes risk score: a practical tool to predict type 2 diabetes risk. , 2003, Diabetes care.

[27]  S. Haffner,et al.  Identification of Persons at High Risk for Type 2 Diabetes Mellitus: Do We Need the Oral Glucose Tolerance Test? , 2002, Annals of Internal Medicine.

[28]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[29]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[30]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[31]  Daniel B. Mark,et al.  TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .